{"id":16397,"date":"2022-12-08T15:31:26","date_gmt":"2022-12-08T14:31:26","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16397"},"modified":"2024-12-11T18:37:56","modified_gmt":"2024-12-11T17:37:56","slug":"profil-de-toxicite-cardiaque-de-lacalabrutinib","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/profil-de-toxicite-cardiaque-de-lacalabrutinib\/","title":{"rendered":"Profil de toxicit\u00e9 cardiaque de l\u2019acalabrutinib"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. : HematoStat.net ; 3 (4) : R67<\/p>\n<p><i><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35917449\/\">Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Bhat SA, Gambril J, Azali L, Chen ST, Rosen L, Palettas M, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood. 17 nov 2022;140(20):2142\u20115<\/a><\/i>.<\/p>\n<h3>R\u00e9sum\u00e9 de l&#8217;article<\/h3>\n<p>La cardiotoxicit\u00e9 peut dans certains cas limiter l\u2019utilisation des inhibiteurs de la tyrosine kinase de Bruton (iTKB). Les auteurs ont \u00e9valu\u00e9 l\u2019incidence des arythmies ventriculaires (AV) symptomatiques chez des patients recevant l\u2019acalabrutinib (acala) pour une leuc\u00e9mie lympho\u00efde chronique. Ces \u00e9v\u00e9nements concernaient 3 % des patients trait\u00e9s par acala ce qui est inf\u00e9rieur au taux observ\u00e9 sous ibrutinib mais reste 8 fois sup\u00e9rieur \u00e0 une population g\u00e9n\u00e9rale similaire.<\/p>\n<h3>Dans nos pratiques<\/h3>\n<p>La survenue de fibrillation atriale (FA) chez des partients trait\u00e9s par iBTK de 1<sup>re<\/sup> g\u00e9n\u00e9ration est un ph\u00e9nom\u00e8ne bien document\u00e9. L\u2019acala, iBTK de 2<sup>e<\/sup> g\u00e9n\u00e9ration, est plus s\u00e9l\u00e9ctif et diminue le risque de FA. Cette \u00e9tude souligne toutefois que le risque cardiaque va au-del\u00e0 de la FA et n\u00e9cessite une surveillance rapproch\u00e9e. Il s\u2019agit d\u2019un effet de classe qui pourrait \u00eatre li\u00e9 \u00e0 la r\u00e9duction de l\u2019activit\u00e9 PI3K-Akt engendr\u00e9 par les iBTK.<\/p>\n<h3>Regard du statisticien<\/h3>\n<p>Ce <i>brief report<\/i> a pour vis\u00e9e l\u2019estimation des risques d\u2019AV chez les patients utilisant l\u2019iTKB. Des \u00e9l\u00e9ments de comparaison permettent d\u2019\u00e9valuer ce risque par rapport \u00e0 l\u2019ibrutinib (dont les \u00e9v\u00e9nements cardio-toxiques sont bien document\u00e9s) et par rapport \u00e0 la normale (allant jusqu\u2019\u00e0 8 fois plus). L\u2019analyse des facteurs de risque quant \u00e0 elle ne se fait que sur une cohorte de patients trait\u00e9s par iTKB.<span class=\"Apple-converted-space\"> <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[126,92,362],"ppma_author":[456],"class_list":["post-16397","post","type-post","status-publish","format-standard","hentry","category-revue-de-presse","tag-acalabrutinib","tag-ibrutinib","tag-itk","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16397"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16397\/revisions"}],"predecessor-version":[{"id":18241,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16397\/revisions\/18241"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16397"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}